News from regeneron pharmaceuticals, inc

Jul 09, 2014, 17:00 ET

Regeneron and Sanofi Announce Positive Results from Phase 2b Study of Dupilumab in Patients with Moderate-to-Severe Atopic Dermatitis

 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi (EURONEXT: SAN and NYSE: SNY) today announced positive results from a Phase 2b...

Jun 27, 2014, 07:17 ET

EYLEA® (aflibercept) Injection Recommended for Approval for the Treatment of Visual Impairment due to Diabetic Macular Edema in the European Union

 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that EYLEA® (aflibercept) Injection has been recommended for approval by...

Jun 12, 2014, 01:00 ET

Sanofi and Regeneron Announce New, Detailed Data from Positive Sarilumab Phase 3 Rheumatoid Arthritis Trial at EULAR

 Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today presented positive results from a phase 3...

Jun 11, 2014, 02:30 ET

EYLEA® (aflibercept) Injection Submitted for EU Marketing Authorization for the Treatment of Patients with Macular Edema Secondary to Branch Retinal Vein Occlusion (BRVO)

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Bayer HealthCare today announced that Bayer HealthCare has submitted an application to the...

Jun 02, 2014, 17:03 ET

Regeneron Announces Winners of the 2014 Regeneron Prize for Creative Innovation

 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the second annual winners of the Regeneron Prize for Creative Innovation, an...

May 30, 2014, 16:05 ET

Regeneron Announces Update to Upcoming 2014 Investor Conference Presentations

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast its management presentation at the following investor conferences: - Jefferies...

May 08, 2014, 06:30 ET

Regeneron Reports First Quarter 2014 Financial and Operating Results

 Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced financial results for the first quarter of 2014 and provided an update on...

May 05, 2014, 08:27 ET

Regeneron and Avalanche Biotechnologies Announce Collaboration to Develop Next-Generation Gene Therapy Products in Ophthalmology

 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Avalanche Biotechnologies, Inc., today announced the formation of a broad collaboration to...

May 02, 2014, 09:30 ET

Regeneron Announces Upcoming 2014 Investor Conference Presentations

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management presentations at the following investor conferences: - Citi Biotech...

Apr 11, 2014, 09:30 ET

Regeneron to Report First Quarter 2014 Financial and Operating Results and Host Conference Call and Webcast on May 8, 2014

 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its first quarter 2014 financial and operating results...

Apr 04, 2014, 16:00 ET

Robert A. Ingram Elected to Regeneron Board of Directors

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it has elected Robert A. Ingram to its Board of Directors.  Regeneron also...

Apr 03, 2014, 16:00 ET

Regeneron Announces Initiative for STEM Education in Hudson Valley

 In a new initiative to promote STEM (Science Technology Engineering Math) education in New York's Hudson Valley, Regeneron Pharmaceuticals,...

Apr 01, 2014, 08:00 ET

Sanofi and Regeneron Report Positive Results With Alirocumab From Phase 2 Japanese Study

Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the first Phase 2 study with...

Mar 27, 2014, 02:00 ET

Sanofi and Regeneron To Present Alirocumab Clinical Data at the American College of Cardiology's 63rd Annual Scientific Session

Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that data from alirocumab clinical...

Mar 03, 2014, 02:00 ET

Bayer HealthCare and Regeneron Announce Regulatory Submission of EYLEA® (aflibercept) Injection for the Treatment of Diabetic Macular Edema in Japan

 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that Bayer HealthCare's Japanese subsidiary, Bayer Yakuhin, Ltd., has submitted...

Feb 24, 2014, 07:30 ET

Regeneron Announces FDA Acceptance of EYLEA® (aflibercept) Injection Supplemental Biologics License Application for the Treatment of Macular Edema Following Branch Retinal Vein Occlusion

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for standard review...

Feb 14, 2014, 09:30 ET

Regeneron Announces Upcoming 2014 Investor Conference Presentations

 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management presentations at the following investor conferences: - 2014...

Feb 11, 2014, 06:30 ET

Regeneron Reports Fourth Quarter and Full Year 2013 Financial and Operating Results

 Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced financial results for the fourth quarter and full year 2013 and provided an...

Feb 10, 2014, 07:30 ET

Two-Year Results From Phase 3 VISTA Trial of EYLEA® (aflibercept) Injection for the Treatment of Diabetic Macular Edema Show Sustained Improvement in Vision

 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Bayer HealthCare today announced that in the Phase 3 VISTA-DME trial of EYLEA®...

Jan 21, 2014, 09:30 ET

Regeneron to Report Fourth Quarter and Full Year 2013 Financial and Operating Results and Host Conference Call and Webcast on February 11, 2014

 Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced that it will report its fourth quarter and full year 2013 financial and...

Organizations in the News

The organizations with the most activity in PR Newswire's News Room

Research and Markets
Analysts Review
ReportBuyer